MA45244A - Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 - Google Patents
Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1Info
- Publication number
- MA45244A MA45244A MA045244A MA45244A MA45244A MA 45244 A MA45244 A MA 45244A MA 045244 A MA045244 A MA 045244A MA 45244 A MA45244 A MA 45244A MA 45244 A MA45244 A MA 45244A
- Authority
- MA
- Morocco
- Prior art keywords
- substituted pyridines
- pyridines used
- dnmt1 inhibitors
- dnmt1
- inhibitors
- Prior art date
Links
- 108010009540 DNA (Cytosine-5-)-Methyltransferase 1 Proteins 0.000 title 1
- 102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000003222 pyridines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662349227P | 2016-06-13 | 2016-06-13 | |
| US201662393256P | 2016-09-12 | 2016-09-12 | |
| US201662412343P | 2016-10-25 | 2016-10-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA45244A true MA45244A (fr) | 2019-04-17 |
Family
ID=59239935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA045244A MA45244A (fr) | 2016-06-13 | 2017-06-13 | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10975056B2 (fr) |
| EP (1) | EP3468953B1 (fr) |
| JP (1) | JP7051829B2 (fr) |
| KR (1) | KR20190017030A (fr) |
| CN (1) | CN109563043B (fr) |
| AU (1) | AU2017283790B2 (fr) |
| CA (2) | CA3026226A1 (fr) |
| CL (1) | CL2018003577A1 (fr) |
| CO (1) | CO2018013717A2 (fr) |
| CR (1) | CR20180580A (fr) |
| DO (1) | DOP2018000273A (fr) |
| ES (1) | ES2993451T3 (fr) |
| IL (1) | IL263163B (fr) |
| JO (1) | JOP20180120A1 (fr) |
| MA (1) | MA45244A (fr) |
| MX (1) | MX391600B (fr) |
| PE (1) | PE20190971A1 (fr) |
| PH (1) | PH12018502633B1 (fr) |
| SG (1) | SG11201809559UA (fr) |
| WO (2) | WO2017216727A1 (fr) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA034786B1 (ru) | 2015-08-13 | 2020-03-20 | Мерк Шарп И Доум Корп. | Циклические динуклеотидные соединения в качестве агонистов sting |
| US11453697B1 (en) | 2015-08-13 | 2022-09-27 | Merck Sharp & Dohme Llc | Cyclic di-nucleotide compounds as sting agonists |
| SI3730487T1 (sl) | 2016-06-13 | 2022-08-31 | Gilead Sciences, Inc. | Azetidinski derivati kot modulatorji FXR (NR1H4) |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences Inc | Fxr (nr1h4) modulating compounds |
| TN2020000158A1 (en) | 2016-10-04 | 2022-04-04 | Merck Sharp & Dohme | BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS |
| JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ， インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
| EP3621624B1 (fr) | 2017-05-12 | 2023-08-30 | Merck Sharp & Dohme LLC | Composés dinucléotidiques cycliques en tant qu'agonistes sting |
| US11285131B2 (en) | 2017-08-04 | 2022-03-29 | Merck Sharp & Dohme Corp. | Benzo[b]thiophene STING agonists for cancer treatment |
| RU2020109328A (ru) | 2017-08-04 | 2021-09-06 | Мерк Шарп И Доум Корп. | Комбинации антагонистов pd-1 и бензо[b]тиофеновых агонистов sting для лечения рака |
| CN109651358B (zh) * | 2017-10-11 | 2023-04-07 | 上海迪诺医药科技有限公司 | 4-氨基吡啶衍生物、其药物组合物、制备方法及应用 |
| WO2019125974A1 (fr) | 2017-12-20 | 2019-06-27 | Merck Sharp & Dohme Corp. | Composés dinucléotidiques cycliques utilisés comme agonistes sting |
| WO2019195124A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Benzothiophènes et composés associés utilisés en tant qu'agonistes de sting |
| WO2019195063A1 (fr) | 2018-04-03 | 2019-10-10 | Merck Sharp & Dohme Corp. | Composés aza-benzothiophènes utilisés en tant qu'agonistes de sting |
| US11225473B2 (en) | 2019-01-15 | 2022-01-18 | Gilead Sciences, Inc. | FXR (NR1H4) modulating compounds |
| EP3927683A1 (fr) | 2019-02-19 | 2021-12-29 | Gilead Sciences, Inc. | Formes solides d'agonistes de fxr |
| CN113480541B (zh) * | 2019-03-07 | 2022-09-02 | 湖南化工研究院有限公司 | 咪唑并吡啶化合物及其中间体的制备方法 |
| WO2022076563A1 (fr) * | 2020-10-07 | 2022-04-14 | University Of Florida Research Foundation, Incorporated | Composés macrocycliques et méthodes de traitement |
| PH12023552345A1 (en) * | 2021-03-02 | 2024-04-22 | Glaxosmithkline Ip Dev Ltd | Substituted pyridines as dnmt1 inhibitors |
| CN113502265B (zh) * | 2021-05-25 | 2024-05-28 | 昭泰英基生物医药（香港）有限公司 | 将t细胞重编程为类nk细胞的诱导剂及其应用 |
| CN113278021B (zh) * | 2021-05-29 | 2022-09-23 | 天津全和诚科技有限责任公司 | 1,7-二氮杂螺[3.5]壬烷-7-甲酸叔丁酯及其草酸盐的制备方法 |
| AU2022370354A1 (en) | 2021-10-19 | 2024-05-30 | Akirabio, Inc. | Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers |
| CN114230459A (zh) * | 2021-12-10 | 2022-03-25 | 武汉九州钰民医药科技有限公司 | 一种化合物的制备方法及分析检测方法 |
| WO2023192629A1 (fr) * | 2022-04-01 | 2023-10-05 | Herophilus, Inc. | Induction de l'expression de mecp2 par des inhibiteurs de l'adn méthyl transférase |
| WO2024156288A1 (fr) * | 2023-01-29 | 2024-08-02 | Shanghai Kygent Pharmaceutical Co., Ltd | Inhibiteurs de dnmt1, compositions pharmaceutiques et applications thérapeutiques |
| WO2025006902A2 (fr) * | 2023-06-29 | 2025-01-02 | Dana-Farber Cancer Institute, Inc. | Synthèse et caractérisation in vitro de chimères ciblant la protéolyse (protacs) pour la dégradation de l'adn méthyltransférase 1 (dnmt1) |
| WO2025085756A1 (fr) * | 2023-10-18 | 2025-04-24 | University Of Florida Research Foundation, Incorporated | Composés macrocycliques et méthodes de traitement |
| WO2025190285A1 (fr) * | 2024-03-12 | 2025-09-18 | Shanghai Kygent Pharmaceutical Co., Ltd | Composés de pyridine, compositions pharmaceutiques et applications |
| CN119306700A (zh) * | 2024-08-28 | 2025-01-14 | 山东大学 | Dnmt1-hdac双靶点抑制剂及其制备方法和应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2030875C (fr) | 1990-11-26 | 2002-07-02 | Alan R.P. Paterson | Methodes et sondes pour le depistage de la nucleoside et methode de fabrication de ces sondes |
| CA2075154A1 (fr) | 1991-08-06 | 1993-02-07 | Neelakantan Balasubramanian | Aldehydes peptidiques utilises comme agents antithrombotiques |
| ZA942125B (en) | 1993-03-26 | 1994-11-10 | Shell Res Ltd | Herbicidal heterocyclic compounds. |
| CZ203798A3 (cs) | 1995-12-29 | 1998-12-16 | Smithkline Beecham Corporation | Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití |
| AU1295597A (en) | 1995-12-29 | 1997-07-28 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
| DE19947154A1 (de) * | 1999-10-01 | 2001-10-04 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| EP1242366A1 (fr) | 1999-12-15 | 2002-09-25 | Axys Pharmaceuticals, Inc. | Salicylamides utiles en tant qu'inhibiteurs des serines proteases |
| US6794506B2 (en) | 2000-07-21 | 2004-09-21 | Elan Pharmaceuticals, Inc. | 3-(heteroaryl) alanine derivatives-inhibitors of leukocyte adhesion mediated by VLA-4 |
| US20030166554A1 (en) | 2001-01-16 | 2003-09-04 | Genset, S.A. | Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists |
| DE10110754A1 (de) * | 2001-03-07 | 2002-09-19 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung |
| DE10134481A1 (de) * | 2001-07-16 | 2003-01-30 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| DE10238113A1 (de) * | 2001-12-11 | 2003-06-18 | Bayer Ag | Substituierte 2-Thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre Verwendung |
| TW200406370A (en) | 2002-06-28 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy)phenoxy alkyl derivatives |
| TW200406152A (en) | 2002-08-30 | 2004-05-01 | Syngenta Participations Ag | 4-(3,3-Dihalo-allyloxy) phenol derivatives having pesticidal properties |
| US6930117B2 (en) | 2002-11-09 | 2005-08-16 | The Procter & Gamble Company | N-alkyl-4-methyleneamino-3-hydroxy-2-pyridones |
| AR042344A1 (es) | 2002-12-11 | 2005-06-15 | Syngenta Participations Ag | Derivados de 4-(3,3 - dihalo - aliloxi) fenol con propiedades pesticidas |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| CA2520323C (fr) | 2003-04-09 | 2013-07-09 | Exelixis, Inc. | Modulateurs de tie-2 et procedes d'utilisation |
| WO2004103954A1 (fr) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | Derive d'amide |
| CN1856307A (zh) | 2003-09-23 | 2006-11-01 | 默克公司 | 喹啉钾通道抑制剂 |
| AU2011253934C1 (en) | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US7776869B2 (en) | 2004-10-18 | 2010-08-17 | Amgen Inc. | Heteroaryl-substituted alkyne compounds and method of use |
| EP1655296A1 (fr) | 2004-10-25 | 2006-05-10 | Graffinity Pharmaceuticals AG | Inhibiteurs de la thrombine |
| WO2006078752A2 (fr) | 2005-01-21 | 2006-07-27 | Methylgene, Inc. | Inhibiteurs d'adn-methyltransferase |
| GB0517740D0 (en) | 2005-08-31 | 2005-10-12 | Novartis Ag | Organic compounds |
| US7825120B2 (en) | 2005-12-15 | 2010-11-02 | Cytokinetics, Inc. | Certain substituted ((piperazin-1-ylmethyl)benzyl)ureas |
| EP2030971B1 (fr) | 2006-06-20 | 2011-10-12 | Ishihara Sangyo Kaisha, Ltd. | Agent de lutte antiparasite contenant un nouveau dérivé de pyridyl-méthanamine ou un sel de celui-ci |
| US20080132525A1 (en) | 2006-12-04 | 2008-06-05 | Methylgene Inc. | Inhibitors of DNA Methyltransferase |
| AU2008211729A1 (en) | 2007-02-01 | 2008-08-07 | Astrazeneca Ab | 5,6,7,8-tetrahydropteridine derivatives as HSP90 inhibitors |
| US20090011994A1 (en) | 2007-07-06 | 2009-01-08 | Bristol-Myers Squibb Company | Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| WO2009034433A2 (fr) | 2007-09-10 | 2009-03-19 | Glenmark Pharmaceuticals, S.A. | Dérivés de 3-azabicyclo [3.1.0] hexane utilisés comme ligands des récepteurs vanilloïdes |
| ES2446932T3 (es) | 2007-10-08 | 2014-03-10 | Advinus Therapeutics Private Limited | Derivados de acetamida como activadores de glucoquinasa, su procedimiento y aplicaciones en medicina |
| US8343966B2 (en) | 2008-01-11 | 2013-01-01 | Novartis Ag | Organic compounds |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| WO2010007756A1 (fr) * | 2008-07-14 | 2010-01-21 | 塩野義製薬株式会社 | Dérivé de pyridine ayant une activité d'inhibition de la ttk |
| UY32055A (es) | 2008-08-19 | 2010-03-26 | Astrazeneca Ab | Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones. |
| WO2010048149A2 (fr) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie |
| AR074760A1 (es) | 2008-12-18 | 2011-02-09 | Metabolex Inc | Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico. |
| WO2010088518A2 (fr) | 2009-01-31 | 2010-08-05 | Kalypsys, Inc. | Modulateurs hétérocycliques du gpr119 pour le traitement de maladies |
| KR101146010B1 (ko) * | 2009-09-10 | 2012-05-16 | 서울대학교산학협력단 | ＴＮＦ-α 매개성 질환의 예방 및 치료용 조성물 |
| US20120238557A1 (en) | 2009-11-13 | 2012-09-20 | Shionogi & Co., Ltd. | Aminothiazine or aminooxazine derivative having amino linker |
| KR101790255B1 (ko) | 2009-12-23 | 2017-10-26 | 다케다 야쿠힌 고교 가부시키가이샤 | Ｓｙｋ 억제제로서의 융합된 헤테로방향족 피롤리디논 |
| CN102884062B (zh) | 2009-12-23 | 2016-08-03 | 嘉世高制药公司 | 氨基嘧啶激酶抑制剂 |
| EP2338888A1 (fr) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Dérivés d'imidazopyridine en tant qu'inhibiteurs JAK |
| WO2011103289A2 (fr) | 2010-02-17 | 2011-08-25 | Jasco Pharmaceuticals, LLC | Inhibiteurs imidazole-2, 4-dione de la caséine kinase 1 |
| WO2011150156A2 (fr) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Composés hétéroarylés et leurs procédés d'utilisation |
| WO2012040636A2 (fr) | 2010-09-24 | 2012-03-29 | The Broad Institute, Inc. | Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase |
| US20120184572A1 (en) | 2011-01-13 | 2012-07-19 | Metabolex, Inc. | Aryl gpr119 agonists and uses thereof |
| CA2824808A1 (fr) | 2011-01-17 | 2012-07-26 | Karyopharm Therapeutics, Inc. | Modulateurs du transport nucleaire contenant des olefines et leurs utilisations |
| WO2012170931A2 (fr) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Composés qui modulent le calcium intracellulaire |
| WO2013019635A1 (fr) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Composés et méthodes |
| WO2013019621A1 (fr) | 2011-07-29 | 2013-02-07 | Tempero Pharmaceuticals, Inc. | Composés et méthodes |
| EP2771012A4 (fr) * | 2011-10-24 | 2015-06-24 | Glaxosmithkline Ip No 2 Ltd | Nouveaux composés |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| NZ706857A (en) | 2012-09-28 | 2018-05-25 | Ignyta Inc | Azaquinazoline inhibitors of atypical protein kinase c |
| JP2017502968A (ja) | 2014-01-21 | 2017-01-26 | ウォックハート リミテッド | ７−オキソ−１，６−ジアザビシクロ［３．２．１］オクタン誘導体及び抗菌剤としてのその使用 |
| WO2015110999A1 (fr) | 2014-01-24 | 2015-07-30 | Piramal Enterprises Limited | Inhibiteurs de ezh2 et leurs utilisations |
-
2017
- 2017-06-13 CA CA3026226A patent/CA3026226A1/fr not_active Abandoned
- 2017-06-13 MX MX2018015483A patent/MX391600B/es unknown
- 2017-06-13 EP EP17733902.5A patent/EP3468953B1/fr active Active
- 2017-06-13 PH PH1/2018/502633A patent/PH12018502633B1/en unknown
- 2017-06-13 MA MA045244A patent/MA45244A/fr unknown
- 2017-06-13 US US16/309,121 patent/US10975056B2/en active Active
- 2017-06-13 SG SG11201809559UA patent/SG11201809559UA/en unknown
- 2017-06-13 AU AU2017283790A patent/AU2017283790B2/en not_active Ceased
- 2017-06-13 CA CA3026211A patent/CA3026211A1/fr active Pending
- 2017-06-13 WO PCT/IB2017/053511 patent/WO2017216727A1/fr not_active Ceased
- 2017-06-13 WO PCT/IB2017/053509 patent/WO2017216726A1/fr not_active Ceased
- 2017-06-13 KR KR1020197000766A patent/KR20190017030A/ko not_active Ceased
- 2017-06-13 CR CR20180580A patent/CR20180580A/es unknown
- 2017-06-13 JP JP2019517187A patent/JP7051829B2/ja active Active
- 2017-06-13 PE PE2018003216A patent/PE20190971A1/es unknown
- 2017-06-13 ES ES17733902T patent/ES2993451T3/es active Active
- 2017-06-13 CN CN201780036908.XA patent/CN109563043B/zh active Active
-
2018
- 2018-11-21 IL IL263163A patent/IL263163B/en unknown
- 2018-12-07 DO DO2018000273A patent/DOP2018000273A/es unknown
- 2018-12-10 JO JOP/2018/0120A patent/JOP20180120A1/ar unknown
- 2018-12-12 CL CL2018003577A patent/CL2018003577A1/es unknown
- 2018-12-18 CO CONC2018/0013717A patent/CO2018013717A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017283790A1 (en) | 2018-11-22 |
| ES2993451T3 (en) | 2024-12-30 |
| BR112018075992A2 (pt) | 2019-04-02 |
| AU2017283790B2 (en) | 2019-08-29 |
| JP2019517596A (ja) | 2019-06-24 |
| US10975056B2 (en) | 2021-04-13 |
| CA3026211A1 (fr) | 2017-12-21 |
| PE20190971A1 (es) | 2019-07-09 |
| KR20190017030A (ko) | 2019-02-19 |
| CN109563043A (zh) | 2019-04-02 |
| CA3026226A1 (fr) | 2017-12-21 |
| JOP20180120A1 (ar) | 2019-01-30 |
| SG11201809559UA (en) | 2018-12-28 |
| IL263163B (en) | 2021-10-31 |
| PH12018502633B1 (en) | 2023-02-01 |
| PH12018502633A1 (en) | 2019-09-30 |
| WO2017216727A1 (fr) | 2017-12-21 |
| EP3468953B1 (fr) | 2024-05-22 |
| WO2017216726A1 (fr) | 2017-12-21 |
| MX391600B (es) | 2025-03-21 |
| CR20180580A (es) | 2019-07-02 |
| EP3468953C0 (fr) | 2024-05-22 |
| DOP2018000273A (es) | 2019-03-31 |
| CN109563043B (zh) | 2022-05-31 |
| IL263163A (en) | 2018-12-31 |
| US20190194166A1 (en) | 2019-06-27 |
| CO2018013717A2 (es) | 2019-01-18 |
| MX2018015483A (es) | 2019-03-18 |
| EP3468953A1 (fr) | 2019-04-17 |
| CL2018003577A1 (es) | 2019-04-05 |
| JP7051829B2 (ja) | 2022-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45244A (fr) | Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1 | |
| MA47460A (fr) | Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase | |
| MA48994A (fr) | Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1 | |
| MA40943A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA40940A (fr) | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines | |
| MA49903A (fr) | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 | |
| EP3386981A4 (fr) | Hétérocycles utiles en tant qu'agents anticancereux | |
| MA46981A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
| MA53150A (fr) | Composés de benzimidazole en tant qu'inhibiteurs de c-kit | |
| MA40774A (fr) | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 | |
| MA41140A (fr) | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg | |
| MA42659A (fr) | Dérivés hétéroaryle utilisés en tant qu'inhibiteurs de parp | |
| MA47123A (fr) | Dérivés de benzooxazole en tant qu'mmunomodulateurs | |
| DK3497103T3 (da) | Pyridopyrimdinon-cdk2/4/6-inhibitorer | |
| MA43862A (fr) | Spiroheptane salicylamides et composés associés en tant qu' inhibiteurs de rock | |
| MA47125A (fr) | Dérivés de pyrazole en tant qu'inhibiteurs de malt1 | |
| MA41551A (fr) | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| MA54567A (fr) | Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma | |
| MA42990A (fr) | Composés utiles en tant qu'immunomodulateurs | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| EP3416964A4 (fr) | Dérivés de carboxamide utiles en tant qu'inhibiteurs de rsk | |
| MA52123A (fr) | Dérivé de 6-pyrimidine-isoindole utilisé en tant qu'inhibiteur de erk1/2 | |
| MA46745A (fr) | Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v |